胰腺癌患者高胆红素血症的管理
本文综述晚期胰腺腺癌患者高胆红素血症的主要病因、治疗及鉴别诊断,并回顾现有药物在髙胆红素血症背景下使用的临床证据及联合方案推荐。髙胆红素血症影响化疗选择,但该场景下化疗证据极少。
要点
- 髙胆红素血症在晚期胰腺癌诊断时及病程中均常见,是化疗选择的关键决定因素。
- 需鉴别髙胆红素血症的病因并给予相应处理。
- 现有药物在该场景的临床证据极少,联合方案推荐基于有限证据。
核心结论
- 髙胆红素血症是晚期胰腺腺癌化疗选择的重要决定因素,但该场景下化疗证据极少。
研究设计与样本
- 综述性文章,总结髙胆红素血症的主要病因、治疗及鉴别诊断,并回顾现有药物临床证据与联合方案推荐。
主要发现
- 髙胆红素血症在晚期胰腺腺癌诊断时及疾病演进过程中均常见。
- 髙胆红素血症决定化疗药物选择,应被视为最相关的情况之一。
- 该场景下化疗使用的证据非常少。
临床怎么用
- 临床需对胰腺癌患者髙胆红素血症进行病因鉴别与处理,并据此选择化疗方案。
局限性
- 该场景下化疗证据极少,相关推荐基于有限证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed.
引用
- Álvarez R, Carrato A, Adeva J, et al. Management of hyperbilirubinaemia in pancreatic cancer patients. Eur J Cancer. 2018. PMID: 29505968. doi:10.1016/j.ejca.2018.01.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。